Company profile
Lantheus Holdings, Inc.
NASDAQ: LNTH · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Bedford, MACIK 0001521036Reports USD
#123 of 1,417 Healthcare companies by revenue43rd-percentile growth
EA Score
79B+FH 85DQ 81GM 55SS 77
v0.1 · 65/100 weight · provisional
↑ operating margin, return on equity · ↓ revenue growth (YoY), listing tenure
Methodology →Revenue TTM
$1.5B
Rev growth YoY (TTM)
+0.6%
Net income (FY)
$233.6M
Employees
1,193
as of 2026-08-06
Market cap
$6.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.5B$1.5B2025
Net income$233.6M$233.6M2025
Operating income$310.8M$310.8M2025
Total assets$2.2B$2.2B2025
Liabilities$1.1B$1.1B2025
Equity$1.1B$1.1B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product33%
PYLARIFY22%
Radiopharmaceutical Oncology22%
Total Precision Diagnostics11%
DEFINITY7%
Techne Lite2%
By geography
UNITED STATES95%
Non-US5%
The read
What is Lantheus Holdings, Inc.’s revenue?
Lantheus Holdings, Inc. booked $1.5B in FY2025 revenue, growing 0.5% year over year — about the middle of the pack among Healthcare companies we track, at a 15.2% net margin.
Peers · Healthcare
American Oncology Network, Inc.——PTC Therapeutics, Inc.72BIntegra LifeSciences Holdings Corporation67BMerit Medical Systems, Inc.83B+National HealthCare Corporation78B+P3 Health Partners Inc.44DKey facts
CEOMary Anne Heino
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBedford, MA
ExchangeNASDAQ: LNTH
Employees1,193
IPO date2015-06-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.